Is OVID or CMPS more profitable?

Ovid Therapeutics' return on equity of -23.64% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Ovid Therapeutics N/A -23.64% -20.52% Compass Pathways N/A -49.63% -13.08%

Ovid Therapeutics (OVID) Competitors

$2.38 -0.05 (-2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$2.45 +0.07 (+2.94%)

As of 07:56 PM Eastern

Compare

OVID vs. CMPS, XERS, OCUL, ANIP, and ETON

Should you buy Ovid Therapeutics stock or one of its competitors? Ovid Therapeutics's main competitors and comparable companies include Compass Pathways (CMPS), Xeris Biopharma (XERS), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), and Eton Pharmaceuticals (ETON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ovid Therapeutics compare to Compass Pathways?

Ovid Therapeutics (NASDAQ:OVID) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Ovid Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 150.52%. Compass Pathways has a consensus price target of $23.36, suggesting a potential upside of 97.69%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Ovid Therapeutics' return on equity of -23.64% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Compass Pathways	N/A	-49.63%	-13.08%

In the previous week, Compass Pathways had 5 more articles in the media than Ovid Therapeutics. MarketBeat recorded 5 mentions for Compass Pathways and 0 mentions for Ovid Therapeutics. Compass Pathways' average media sentiment score of 0.35 beat Ovid Therapeutics' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Compass Pathways	Neutral

Ovid Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market.

Ovid Therapeutics has higher revenue and earnings than Compass Pathways. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.52	-$17.41M	-$0.31	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ovid Therapeutics beats Compass Pathways on 8 of the 14 factors compared between the two stocks.

How does Ovid Therapeutics compare to Xeris Biopharma?

Ovid Therapeutics (NASDAQ:OVID) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Ovid Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Ovid Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 150.52%. Xeris Biopharma has a consensus price target of $12.80, suggesting a potential upside of 39.81%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ovid Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Ovid Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Xeris Biopharma	-5.12%	338.21%	3.50%

In the previous week, Xeris Biopharma had 13 more articles in the media than Ovid Therapeutics. MarketBeat recorded 13 mentions for Xeris Biopharma and 0 mentions for Ovid Therapeutics. Xeris Biopharma's average media sentiment score of 0.64 beat Ovid Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Xeris Biopharma	Positive

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Ovid Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.52	-$17.41M	-$0.31	N/A
Xeris Biopharma	$291.85M	5.72	$550K	-$0.11	N/A

Summary

Ovid Therapeutics beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Ocular Therapeutix?

Ovid Therapeutics (NASDAQ:OVID) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ovid Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

In the previous week, Ocular Therapeutix had 13 more articles in the media than Ovid Therapeutics. MarketBeat recorded 13 mentions for Ocular Therapeutix and 0 mentions for Ovid Therapeutics. Ocular Therapeutix's average media sentiment score of 0.08 beat Ovid Therapeutics' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Ocular Therapeutix	Neutral

Ovid Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Ovid Therapeutics' return on equity of -23.64% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

Ovid Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.52	-$17.41M	-$0.31	N/A
Ocular Therapeutix	$51.95M	29.91	-$265.94M	-$1.42	N/A

Ovid Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 150.52%. Ocular Therapeutix has a consensus target price of $25.29, suggesting a potential upside of 257.40%. Given Ocular Therapeutix's higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Ovid Therapeutics beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to ANI Pharmaceuticals?

Ovid Therapeutics (NASDAQ:OVID) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Ovid Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 150.52%. ANI Pharmaceuticals has a consensus target price of $98.00, suggesting a potential upside of 35.31%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ovid Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

ANI Pharmaceuticals has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	64.52	-$17.41M	-$0.31	N/A
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.61

Ovid Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Ovid Therapeutics. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 0 mentions for Ovid Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Ovid Therapeutics' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
ANI Pharmaceuticals	Positive

ANI Pharmaceuticals has a net margin of 11.07% compared to Ovid Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

Summary

ANI Pharmaceuticals beats Ovid Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Ovid Therapeutics compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Eton Pharmaceuticals currently has a consensus target price of $67.50, indicating a potential upside of 25.95%. Ovid Therapeutics has a consensus target price of $6.00, indicating a potential upside of 150.52%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Eton Pharmaceuticals had 7 more articles in the media than Ovid Therapeutics. MarketBeat recorded 7 mentions for Eton Pharmaceuticals and 0 mentions for Ovid Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.71 beat Ovid Therapeutics' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eton Pharmaceuticals	Positive
Ovid Therapeutics	Neutral

Eton Pharmaceuticals has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	19.16	-$4.60M	$0.38	141.04
Ovid Therapeutics	$7.25M	64.52	-$17.41M	-$0.31	N/A

Eton Pharmaceuticals has a net margin of 12.02% compared to Ovid Therapeutics' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Ovid Therapeutics	N/A	-23.64%	-20.52%

Eton Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eton Pharmaceuticals beats Ovid Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OVID vs. The Competition

Export

Metric	Ovid Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$474.57M	$12.27B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.54%	16.77%
P/E Ratio	-7.68	794.62	273.67	26.04
Price / Sales	293.63	757.46	612.51	90.64
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	2.38	10.46	10.92	6.30
Net Income	-$17.41M	$2.83B	$3.50B	$361.43M
7 Day Performance	-0.83%	-1.65%	-2.11%	-1.67%
1 Month Performance	-12.18%	-5.77%	-6.34%	-3.94%
1 Year Performance	45.12%	-3.80%	8.81%	2.77%

Ovid Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OVID Ovid Therapeutics	1.7519 of 5 stars	$2.38 -2.1%	$6.00 +152.1%	+77.4%	$474.57M	$1.58M	N/A	23	Positive News
CMPS Compass Pathways	2.2823 of 5 stars	$12.89 -2.6%	$23.36 +81.3%	+107.1%	$1.78B	N/A	N/A	156	News Coverage
XERS Xeris Biopharma	3.7827 of 5 stars	$9.78 -0.5%	$12.80 +30.9%	+15.5%	$1.78B	$291.85M	N/A	435	News Coverage Insider Trade High Trading Volume
OCUL Ocular Therapeutix	2.701 of 5 stars	$7.79 +1.6%	$25.75 +230.8%	-34.0%	$1.71B	$51.95M	N/A	325	News Coverage Analyst Forecast
ANIP ANI Pharmaceuticals	4.439 of 5 stars	$72.86 -2.6%	$98.00 +34.5%	-19.1%	$1.67B	$883.37M	15.70	970	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OVID) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ovid Therapeutics (OVID) Competitors

OVID vs. CMPS, XERS, OCUL, ANIP, and ETON

How does Ovid Therapeutics compare to Compass Pathways?

Summary

How does Ovid Therapeutics compare to Xeris Biopharma?

Summary

How does Ovid Therapeutics compare to Ocular Therapeutix?

Summary

How does Ovid Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Ovid Therapeutics compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ovid Therapeutics (OVID) Competitors

OVID vs. CMPS, XERS, OCUL, ANIP, and ETON

How does Ovid Therapeutics compare to Compass Pathways?

Do analysts prefer OVID or CMPS?

Is OVID or CMPS more profitable?

Does the media refer more to OVID or CMPS?

Which has more volatility and risk, OVID or CMPS?

Which has stronger valuation & earnings, OVID or CMPS?

Do institutionals & insiders hold more shares of OVID or CMPS?

Summary

How does Ovid Therapeutics compare to Xeris Biopharma?

Which has more risk and volatility, OVID or XERS?

Do analysts rate OVID or XERS?

Is OVID or XERS more profitable?

Does the media prefer OVID or XERS?

Do insiders and institutionals hold more shares of OVID or XERS?

Which has higher valuation and earnings, OVID or XERS?

Summary

How does Ovid Therapeutics compare to Ocular Therapeutix?

Do insiders & institutionals hold more shares of OVID or OCUL?

Which has more volatility and risk, OVID or OCUL?

Does the media prefer OVID or OCUL?

Is OVID or OCUL more profitable?

Which has stronger earnings & valuation, OVID or OCUL?

Do analysts rate OVID or OCUL?

Summary

How does Ovid Therapeutics compare to ANI Pharmaceuticals?

Do analysts rate OVID or ANIP?

Which has stronger valuation and earnings, OVID or ANIP?

Which has more risk and volatility, OVID or ANIP?

Do insiders and institutionals believe in OVID or ANIP?

Does the media refer more to OVID or ANIP?

Is OVID or ANIP more profitable?

Summary

How does Ovid Therapeutics compare to Eton Pharmaceuticals?

Do analysts prefer ETON or OVID?

Does the media prefer ETON or OVID?

Which has preferable earnings & valuation, ETON or OVID?

Is ETON or OVID more profitable?

Which has more risk and volatility, ETON or OVID?

Do institutionals and insiders believe in ETON or OVID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OVID vs. The Competition

Ovid Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools